Refine by
Heart Valve Articles & Analysis
56 news found
It was another first for EchoPixel when its Holographic Therapy Guidance (HTG) was used in a congenital heart surgery at Cincinnati Children’s Hospital Medical Center. ...
” Confluent supports some of the fastest growing medical device markets such as Interventional Neurovascular, Electrophysiology, Structural Heart, and Peripheral Vascular. As a result of the double-digit growth of these currently served markets, a substantial number of new products are coming into production and will utilize this new facility space immediately. ...
Currently, it is unknown how much the company is planning to raise or where the funds will be spent. Anteris is a structural heart company, providing solutions for heart valves. Earlier this week, the company received a patent from the Australian Patent Office for its sterilised packaging system for catheters. ...
Xeltis currently has three restorative devices in clinical trial phase, including aXess – a restorative access graft for dialysis; XABG – which is a coronary artery bypass graft; and its pulmonary heart valve, which was the first ever synthetic valve to enter a pivotal trial (Xplore2/Pivotal) in July this year. ...
” More specifically, the testing range of T,C&A Lab encompasses the following: l Repair materials for the skeletal-muscle system such as bones, teeth, joints, and tendons l Soft tissue materials such as skin, esophagus, respiratory tract, bladder and other l Cardiovascular system materials such as artificial heart valves, blood vessels, and ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater ...
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)'s Wayne Paterson tells Proactive about the 30-day follow-up data just in from the company’s flagship heart valve, currently being tested in humans for the first time. The valve solves the problem of younger and more active heart patients who need a valve ...
I am pleased to say, that following IDE approval of the ALIGN-AR Trial in August 2021, patient enrollment remains on track as we diligently work to achieve our ultimate goal of receiving U.S. FDA approval for the Trilogy Heart Valve System.” “With the addition of the TrilogyTM, Peijia will have a more comprehensive product portfolio to better serve ...
BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, and the Montreal Heart Institute (MHI), a world-renowned, ultra-specialized cardiology center, announced they are partnering to develop a new cardiovascular training solution to help cardiologists rehearse and train for complex valve-in-valve ...
ByBIOMODEX
Confluent provides a broad range of capabilities including developing and manufacturing components, delivery systems and finished devices for medical device OEMs in many of the fastest growing healthcare subsectors, including neurovascular, structural heart, electrophysiology, aortic intervention, peripheral vascular and ENT. ...
” Eliane Schutte, Xeltis CEO, added: “EIB financial support can make the difference in the time our restorative heart valves and blood vessels reach patients that today have limited or no options at all for their conditions. ...
JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. ...
Together with him, we have evaluated in which part of a transcatheter heart valve implantation our navigation technology could provide benefits. ...
Phillip Chan, Chief Executive Officer of CytoSorbents, stated, “Today, infective endocarditis makes up a minor part of our overall usage and revenue in cardiac surgery and we believe that CytoSorb will continue to be used in selected infective endocarditis populations. For example, prosthetic heart valve endocarditis is associated with very high mortality ...
Dr Meduri is a recognized leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees. ...
Scott has more than two decades of experience in the medical technology industry, including with prosthetic heart valves, heart valve repair, orthopedic surgery, stents, blood pumps, TETS, robotic prostheses / orthoses and many more. ...
JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk aortic ...
Scott Lim, Medical Director of the Advanced Cardiac Valve Center at the University of Virginia (Charlottesville, VA) and Dr. ...
atHeart Medical announced today the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. The initial patients were treated by Dr. Thomas Jones, Cardiac ...
RVOT reconstruction is a procedure needed to correct certain congenital heart defects. Following implantation, Xeltis’ synthetic restorative pulmonary heart valves evolve into fully functioning, natural heart valves through colonization by the patient’s own tissue. ...